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Abstract: Background: The parameter uncertainty in the six-dimensional health state short form
(SF-6D) value sets is commonly ignored. There are two sources of parameter uncertainty: uncertainty
around the estimated regression coefficients and uncertainty around the model’s specification. This
study explores these two sources of parameter uncertainty in the value sets using probabilistic
sensitivity analysis (PSA) and a Bayesian approach. Methods: We used data from the original
UK/SF-6D valuation study to evaluate the extent of parameter uncertainty in the value set. First, we
re-estimated the Brazier model to replicate the published estimated coefficients. Second, we estimated
standard errors around the predicted utility of each SF-6D state to assess the impact of parameter
uncertainty on these estimated utilities. Third, we used Monte Carlo simulation technique to account
for the uncertainty on these estimates. Finally, we used a Bayesian approach to quantifying parameter
uncertainty in the value sets. The extent of parameter uncertainty in SF-6D value sets was assessed
using data from the Hong Kong valuation study. Results: Including parameter uncertainty results
in wider confidence/credible intervals and improved coverage probability using both approaches.
Using PSA, the mean 95% confidence intervals widths for the mean utilities were 0.1394 (range:
0.0565–0.2239) and 0.0989 (0.0048–0.1252) with and without parameter uncertainty whilst, using
the Bayesian approach, this was 0.1478 (0.053–0.1665). Upon evaluating the impact of parameter
uncertainty on estimates of a population’s mean utility, the true standard error was underestimated
by 79.1% (PSA) and 86.15% (Bayesian) when parameter uncertainty was ignored. Conclusions:
Parameter uncertainty around the SF-6D value set has a large impact on the predicted utilities
and estimated confidence intervals. This uncertainty should be accounted for when using SF-6D
utilities in economic evaluations. Ignoring this additional information could impact misleadingly on
policy decisions.
Keywords: parameter uncertainty; health utility; Bayesian methods; SF-6D
1. Introduction
The need to appropriately quantify the health benefits produced by competing healthcare strategies
in terms of quality-adjusted life years (QALYs) has become an increasingly important consideration
for decision makers tasked with allocating healthcare funding. In the National Health Service (NHS)
for England and Wales, the National Institute for Health and Care Excellence (NICE) considers the
use of QALYs as a key requirement for any health technology submission undergoing the Institute’s
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appraisal process [1]. The QALY is a composite outcome that combines mortality and morbidity effects
into a single numeraire. The most recent NICE guide to the methods of technology appraisal stipulates
that morbidity should be measured using a preference-based measure of health-related quality of life
(HRQoL), and currently recommends using the EuroQol five-dimensional (EQ-5D-3L) [2].
Heath state values deriving the QALYs incorporated in cost-effectiveness analysis (CEA) are
obtained from a large variety of preference-based measures, including the EQ-5D questionnaire
three-level and five-level versions [2], health utilities index 2 (HUI2) and 3 [3,4], 15D [5,6], Assessment
of Quality of Life [7], Quality of Well-Being scale (QWB) Q5 [8] and the six-dimensional health state
short form (derived from a short-form 36 health survey) (SF-6D) [9].
Measures of HRQoL such as the EQ-5D-3L, SF-6D, and HUI2 consist of a series of statements
asking respondents to value their own health, for example the SF-6D consists of six statements, with
between four and six response choices, giving a total of 18,000 health states. It is not feasible to value
all possible health states, hence only a selection of these are typically measured. These states will have
been selected based on designs, such as orthogonality, to ensure that those selected are representative
of the full set of possible health states; they are also selected so that utility preference weights for all
states can be estimated using statistical models.
The statistical models fitted to health states (N3 model for EQ-5D-3L [10], SF-6D [9] and HUI2 [11])
will consist of one or more parameter estimates (known as preference weights) and, for each estimate,
there will be a measure of uncertainty—for example, a standard error. When the preference weights
(point estimates of the model parameters) are applied to other datasets to estimate utility values, which
are then used to estimate QALYs, this measure of uncertainty is typically ignored. Although there is no
clear reason for not including this information in tariffs associated with preference-based instruments,
it is possible that at the time that methods for devising tariffs were developed, the methodological
and computational challenges were insurmountable. Thus, economic evaluations that derive cost per
QALY estimates from these models do not present the full uncertainty around the utility estimate, as
noted by Ara and Wailoo [12].
The two main sources of parameter uncertainties were brought to light by Gray et al. [13], who
distinguished between parameter uncertainty around the coefficients and model uncertainty around
the model’s specifications. In fact, they deduced that parameter uncertainty around the coefficients is
of little importance in the estimated confidence intervals for incremental QALY, and thus it could be
ignored. However, Pullenayegum et al. [14] concluded that model uncertainty around the model’s
specifications constitutes a major source of uncertainty in value sets, hence it is cardinal to the analysis.
Probability distributions are commonly used to reflect uncertainty in themean parameter estimates
used to populate a cost-effectiveness model, and their impact on the study results is typically explored
by means of probabilistic sensitivity analysis (PSA). This approach assigns appropriate distributions to
model parameters and use simulation methods to capture uncertainty, in a similar way to those used
by Young and Thompson [15] to capture model parameter uncertainty in published prognostic models.
However, this approach only captures the sampling uncertainty that arises as a result of the study
population completing a health-related quality of life instrument. Sampling uncertainty is inherent in
the values assigned to individual health states arising from direct valuation methods, yet this is not
captured under the current practice of ascribing point estimates to health state values. Additionally,
there is no estimate of variance in those health state values currently derived through interpolation
methods based on the sample of directly valued states. Alternatively, Pullenayegum et al. [14]
developed a Bayesian approach to quantifying parameter uncertainty in the value sets, which accounts
for parameter uncertainty around the estimated regression coefficients, and illustrated its impact on
studies that use the EQ-5D-3L to measure health utility.
The aim of this paper is to illustrate the extent of parameter uncertainty through applying PSA
and the Bayesian methods to explore the two sources of uncertainties in value sets when an HRQoL
measure is used to compute the population’s mean utility. First, we will demonstrate that the parameter
uncertainty in the Brazier model [9] creates discrepancies between the predicted and the observed
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mean utilities and serves as a guide for the PSA to propagate parameter uncertainty. Then, parameter
uncertainty, accounting for both uncertainty around the coefficient (estimated in the Brazier model)
and uncertainty around the model’s specifications, will be quantified using a Bayesian approach,
allowing us to estimate parameter uncertainty for the Brazier model and show its impact on studies
measuring health utility using the SF-6D. For this reason, we will use the SF-6D value set from the
UK valuation study specifically gathered from a sample of 4596 Hong Kong (HK) general population
using regression coefficients and their intercorrelation, and standard errors.
2. Methods
2.1. The SF-6D
The SF-6D stands for the short-form six-dimensions value set, derived from the original short-form
36 (SF-36). It is composed of six health dimensions, including physical functioning, role limitation,
social functioning, bodily pain, mental health and vitality, each having between four and six levels [9].
Defining a health state requires choosing a level from each dimension, hence creating 18,000 possible
combinations. Since every possible health state is described by six digits, from 1 to 6, thus the perfect
health state (full health) is indicated by the combination 111111, whereas the “pits” (worst health state)
is indicated by 645655.
2.2. The Valuation Survey and Data Set
2.2.1. UK
The SF-6D UK value set was derived from a sample of 249 health states described through the
SF-6D and then valued by a representative sample of the UK population (n = 836). The selection
methods of respondents along with health states are discussed elsewhere [9]. Of the original 836
respondents, a total of 225 respondents had to be excluded for several reasons. Each of the total
611 included respondents valued six health states according to the McMaster ‘ping pong’ variant of
the standard gamble (SG) technique, giving 3666 valuations. Of these, 148 missing values from 117
respondents were present, thereby resulting in a total of 3518 observed SG valuations across the 249
health states. Further details pertaining to the valuation of the 249 SF-6D UK health states can be found
in [9].
2.2.2. Hong Kong
The HK study comprised a sample of 197 health states (selected using the same approach as
the UK procedures) which were valued using the same valuation procedures as those in the UK
study [16]. Each respondent was asked to rank and value eight health states, and the interview
procedure was modelled on the basis of that in the UK study. Out of the original 641 respondents, a
total of 59 respondents were disqualified, leaving 582 respondents’ data for the analysis. Each of the
582 respondents made eight SG valuations, giving 4596 valuations. Of these, 60 missing health state
values were present and so 4596 observed SG valuations across 197 health states were finally included
in the analysis. A detailed description to the valuation of the 197 SF-6D HK health states has been
reported elsewhere [16].
2.2.3. Modelling
Generally, a model for health state valuations can be expressed as
yi j = f (xi j,α j) + εi j (1)
where, for i = 1, 2, . . . , n j and j = 1, 2, . . . , m, xij represents the ith health state valued by respondent
j with the dependent variable yij being the adjusted SG score. Two sets of zero-mean, independent
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terms of random effects are involved in this general model. First, εi j is a random observation-related
error term, while α j is a respondent-j-related term accounting for the individual characteristics.
Respondent j’s health state utility has been defined by Brazier et al. [9] by the following model
f (xi j,α j) = µ+ θ
′I(xi j) + α j (2)
where µ and θ are unknown parameters, and I(xi j) is a vector of dummy explanatory variables.
Considering a simple case with no interactions, I(xi j) would be a vector of terms Iδλ(xi j) for each level
λ > 1 of dimension δ of the SF-6D. For instance, I32(xij) is level λ = 2 (health limits social activities
a little of the time) of dimension δ = 3 (social functioning). Moreover, for any given health state xij,
Iδλ(xi j) is defined as:
Iδλ(xi j)= 1 if, for state xi j, dimension δ is true at level λ
Iδλ(xi j)= 0 if, for state xi j, dimension δ is not true at level λ
Overall, the 25 defined terms have level λ = 1 as the baseline for each dimension. Hence, the
health state utility value for state 111111 is represented by the intercept parameter µ, which, by adding
it to the sum of the coefficients θδλ of the ‘on’ dummies, derives the value of any other state. For
example, health state utility value for state 111215 is: µ+ θ42 + θ65.
Broadly, interactions between the levels of different dimensions can be accounted for by including
other dummy variables in I(xi j). The term MOST, in the model selected by Brazier et al. [9], fulfilled
this action by having a value of 1 should any dimension in the health state be at one of the most severe
levels (Most severe is defined as levels 4 to 6 for physical functioning, levels 3 and 4 for role limitation,
4 and 5 for social functioning, mental health and vitality, and 5 and 6 for pain.), and 0 in other cases.
The generalized least square (GLS) model and maximum likelihood can estimate this random
effect model. Additionally, since α j has a mean of zero, then the population health state utility for state
x in this model is simply expressed as µ+ θ′I(x).
However, the within- and between-respondent error terms are connected in those models, hence
the RandomEffect (RE)model, an improved specification, separates those error terms by acknowledging
that the error may not be independent of the respondent, namely
ui + ei j
where ui is the respondent specific variation, assumed to be random across individual respondents, and
eij is an error term for the jth health state valuation of the ith individual, assumed to be random across
observations. Additionally, this model assumes that the allocation of health states to respondents is
random, i.e., cov(ui, eij) = 0.
Here, the re-estimation of the Brazier model (Equation (2)) from the original data provided a
covariance matrix and standard errors for each coefficient. This re-estimation was used to compute
mean utility values and respective standard errors for each of the 249 health states of the valuation
study. Despite the misspecification resulting from omitted variables or incorrect functional errors in the
published Brazier model, the main aim of this paper is to examine the consequences of incorporating
parameter uncertainty in the existing model rather than to propose a different model specification.
2.2.4. PSA Approach to Parameter Uncertainty in the Value sets
Economic valuations calculate utilities for patients based on the point estimate of the utility for
each health state, while ignoring the existing parameter uncertainty in the value sets. In this paper, the
impact of parameter uncertainty is generally examined in the SF-6D UK valuations on health utility
measurement, and particularly quantified in the valuations when the SF-6D is used to measure a
population’s mean utility.
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2.2.5. HK Population’s Mean Utility Using Regression Coefficients Only
The mean utility and 95% confidence interval for the HK survey population became readily
available through applying the derived UK model to the HK survey population. In other terms, the
value of any of the HK states in the HK study were derived by summing the coefficients θδλ of the ‘on’
dummies, using only the regression coefficients obtained from the UK model.
2.2.6. HK Population’s Mean Utility Using Regression Coefficients and Their Standard Errors
The uncertainty in the regression coefficients was accounted for using the Monte Carlo simulation
techniques, which resulted in the generation of 10,000 sets of multivariate normally distributed
regression coefficients. The means and standard errors of the 10,000 generated sets mimicked those
of the sets derived from the RE model fitted to the UK data. The statistical computer package R
was used to generate these results. After using all the 10,000 sets of regression coefficients to derive
UK model scores, they were applied to the HK cohort in order to generate 10,000 sets for the HK
survey population, for which the mean utilities, overall mean utilities and 95% confidence intervals are
readily available.
2.2.7. Bayesian Approach to Parameter Uncertainty in the Value Sets
We then used a Bayesian approach similar to the approach used by Pullenayegum et al. [14] to
quantify parameter uncertainty in the value sets, considering both parameter uncertainty around the
regression coefficients and parameter uncertainty around the specification of the model. Bayesian
analysis rests upon computing the posterior probability distribution for model parameters, thusmaking
it easy to characterize parameter uncertainty. It is in this sense that Bayesian methods are getting very
popular in economic evaluations.
For respondent j, the health state utility of state xij is
f
(
xi j, δi
)
= µ+ θ′I
(
xi j
)
+ α j + δi (3)
where δi acknowledges the possibility of model misspecification, which is equal to zero i.e., δi = 0
for all i if there is no model misspecification. We assigned independent normal distributions to the
respondent residual and model misspecification terms
δi ∼ N
(
0, σ2δ
)
, α j ∼ N
(
0, σ2α
)
where σ2
δ
and σ2α are further parameters to be estimated.
The specialist software WinBUGS (version 1.4; MRC Biostatistics unit: Cambridge, UK) facilitated
the fitting of the model using the Bayesian Markov Chain Monte Carlo (MCMC) simulation
method [17,18]. The relevant code is available from the corresponding author. The prior distributions
for all the regression coefficients were defined to be Normal (0, 106); in other words, they were centered
on 0 with a large non-informative variance. The latter are not defined in WinBUGS, but instead
precisions are specified as τ = 1/σ2. Since τ is the inverse of a variance parameter (always an absolute
value), an additional minimally informative prior was required, hence, the common choice of Gamma
(0.001, 0.001).
σ2δ, σ
2
α ∼ InverseGamma(0.001, 0.001)
Initially, 10,000 iterations were run as a “burn in” for the MCMC sampler to reach convergence,
which was assessed by Gelman and Rubin diagnostic [19]. The process involved starting two parallel
chains from scattered starting values and monitoring the within-chain and between-chain variance
until reaching convergence at 1. Afterwards, an additional 10,000 iterations were run for parameters
estimation purposes.
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We next considered the impact of parameter uncertainty in the value sets on studies using the
SF-6D to estimate mean health utility. In particular, we quantified the impact of parameter uncertainty
in the valuations when the SF-6D is used to measure the mean utility of a population. To meet this
objective, we used the UK valuation study to estimate utility values for the full set of health states and
then applied this value set to SF-6D health states collected from a sample of 4596 HK general population.
The mean utility for the SF-6D HK population was computed by first using the valuation sample
to estimate utility values for the full set of health states and then fitting the Pullenayegum model [14]
to the HK data as follows
Utilityj = fi(j)
where i(j) is subject j’s health state and j = 1, ..., 4596
i(j)~Multinomial(p)
where p is a vector of probabilities where the ith element pi represents the probability of a randomly
selected respondent having self-reported health state i, and prior information
p ∼ Dirichlet (α), α = (α1,α2, . . . ,α18000)
with α1 = 1/18000 for i = 1, . . . , 18000. Therefore, the mean utility f for the SF-6D HK population is∑18000
i=1 piui with variance
var
(
f
)
= E
{
var( f |value set )
}
+ var
{
E( f
∣∣∣∣value set)
}
(4)
As already mentioned in [14], the variance in the mean utility f for the SF-6D HK respondents is
equal to the variance in the sample mean when ignoring parameter uncertainty in the value set plus
the variance in the sample mean as the value set varies over its posterior distribution.
3. Results
Parameter Uncertainty in the SF-6D UK Value Set
In total, 25 health states valued in the UK sample were systematically selected from the initial 249
health states. Table 1 shows the observed sample mean health state utility and the predicted mean
and standard deviation for the population’s mean health state utility with and without parameter
uncertainty for the 25 health states. As observed, the standard errors of the mean utilities for all health
states when parameter uncertainty is tolerated using the PSA approach were larger than those ignoring
parameter uncertainty. Therefore, the mean utilities of the 25 valued health states have slightly wider
95% confidence intervals than those without parameter uncertainty. This is reflected in Figure 1a,
showing the estimates and 95% confidence intervals for the mean utilities of the 25 health states.
Evidently, tolerating the possibility of parameter uncertainty improves coverage probability through
wider confidence intervals.
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Table 1. Inference for a selection of health states.
Brazier Model [9]
Probabilistic Sensitivity
Analysis (PSA)
Bayesian
Health State (HS)
Number
HS Observed Predicted
Standard
Deviation (SD)
Predicted SD Predicted SD
1 111111 1.0000 1.0000 0.0000 1.0000 0.0000 1.0000 0.0000
2 112543 0.6070 0.6648 0.0252 0.6648 0.0253 0.6386 0.0393
3 122211 0.6927 0.8588 0.0227 0.8590 0.0224 0.8384 0.0377
4 133132 0.5691 0.7503 0.0247 0.7500 0.0246 0.7212 0.0391
5 144144 0.6842 0.6896 0.0221 0.6897 0.0219 0.6718 0.0364
6 212453 0.6483 0.6396 0.0259 0.6393 0.0261 0.6406 0.0381
7 221535 0.6960 0.6174 0.0255 0.6171 0.0254 0.6247 0.0387
8 232111 0.7589 0.7550 0.0251 0.7550 0.0247 0.7283 0.0395
9 244313 0.6343 0.7085 0.0265 0.7083 0.0263 0.7023 0.0406
10 315515 0.5587 0.6295 0.0259 0.6294 0.0258 0.6342 0.0370
11 323153 0.5656 0.6623 0.0241 0.6621 0.0240 0.6427 0.0357
12 331244 0.7450 0.6620 0.0246 0.6621 0.0247 0.6515 0.0414
13 342322 0.7000 0.6615 0.0249 0.6616 0.0251 0.6518 0.0378
14 412152 0.5010 0.6481 0.0258 0.6483 0.0259 0.6413 0.0389
15 423333 0.5725 0.6678 0.0224 0.6676 0.0222 0.6630 0.0359
16 431443 0.6133 0.6323 0.0248 0.6323 0.0250 0.6123 0.0379
17 442343 0.6500 0.5800 0.0258 0.5803 0.0256 0.5835 0.0388
18 513531 0.5992 0.7132 0.0230 0.7129 0.0231 0.6760 0.0378
19 531635 0.4386 0.5280 0.0231 0.5275 0.0229 0.5249 0.0358
20 535422 0.4771 0.6108 0.0248 0.6107 0.0247 0.6031 0.0368
21 542345 0.6446 0.5484 0.0246 0.5489 0.0243 0.5453 0.0367
22 545122 0.5517 0.6461 0.0227 0.6463 0.0225 0.6417 0.0367
23 614434 0.6523 0.6212 0.0277 0.6208 0.0276 0.6252 0.0387
24 625141 0.7030 0.5254 0.0242 0.5258 0.0243 0.5481 0.0384
25 635255 0.4560 0.3921 0.0218 0.3922 0.0219 0.4328 0.0385
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(b) 
Figure 1. Estimates and 95% intervals for the 25 selected health states. The black circles give the
observed mean utilities for each valued health state. The gray crosses and lines indicate the predicted
means and 95% confidence intervals, ignoring parameter uncertainty. The black lines are the 95%
confidence intervals from (a) the probabilistic sensitivity analysis (PSA) approach and (b) the Bayesian
approach, respectively, that acknowledge uncertainty.
The Supplementary Material shows the inference for the mean health state utility values of the 249
health states valued in the sample. Across all 249 states, the mean 95% confidence intervals widths are
0.0942 (range: 0.0480–0.1149) and 0.0285 (range: 0.002–0.0483) with and without parameter uncertainty,
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respectively, with a difference of 0.0657. Further, only 15% of the observed means fell within the 95% CI
when ignoring parameter uncertainty, in comparison to 36% when parameter uncertainty is considered.
Wenowuse aBayesian approach toquantifyingparameteruncertainty in thevalue sets, considering
both parameter uncertainty around the regression coefficients and parameter uncertainty around the
specification of the model. The final two columns of Table 1 present the posterior predicted mean
and standard deviation for the population mean health state utility f
(
xi j, δi
)
of those 25 health states
included in the valuation study. Acknowledging the possibility of model misspecification leads to a
further increase in the standard errors of the mean unities for all health states, and therefore wider
credible intervals and improved coverage probability are obtained. This can also be seen from Figure 1b,
which shows the estimates and 95% confidence intervals for the mean utilities of the 25 selected health
states. As can be seen, acknowledging the possibility of model uncertainty leads to wider confidence
intervals and improved coverage probability. Finally, across all 249 states that were used in the study,
the mean 95% credible intervals width is 0.1478 (range: 0.053–0.1665), and 54% of the observed means
fell within the 95% credible intervals.
We finally quantify the impact of parameter uncertainty in the valuations when the SF-6D is used
to estimate a population’s mean utility. This is achieved by using the UK valuation study to estimate
utility values for the full set of health states and then applying this value set to SF-6D health states
obtained from a sample of 4596 HK general population. Given the HK valuations and using the PSA
approach, the mean health utility was found to be 0.576 with a standard error of0.001689. Ignoring
parameter uncertainty in the value set, the standard error of the measurement sample’s mean utility
was found to be 0.000353. This implies that the true standard error was underestimated by 79.1% when
parameter uncertainty was not accounted for. This is also the case using the Bayesian approach, as the
true standard error was underestimated by 86.15% when ignoring parameter uncertainty (see Table 2).
Table 2. Impact of parameter uncertainty in the value set on estimates of a population’s mean
health utility.
PSA Bayesian
Estimate
Standard
Error (SE)
Variance Estimate SE Variance
Mean health utility
1. Usual estimate of uncertainty
2. Uncertainty due to the value set
0.576 0.001689017 0.000002853 0.589 0.01284 0.000164866
0.000353456 0.000000125 0.001778340 0.000003162
0.001651620 0.000002728 0.012716254 0.000161703
Total 0.000002853 0.000164866
4. Discussion
In this paper, we have explored the two sources of uncertainty: (1) parameter uncertainty around
the coefficients estimated in the Brazier et al. model and (2) model uncertainty around the specification
of the model used to estimate the Brazier et al. model. We have used PSA and Bayesian methods
to account for both types of uncertainty simultaneously in the value set when a measure of HRQoL
(SF-6D here) is used to measure a population’s mean utility. We have shown, using both approaches,
that parameter uncertainty around the value sets is substantial and should not be ignored in economic
evaluations, and thus should be fully represented when reporting results. This finding is in line with
previous work [13] which suggested that the impact of parameter uncertainty due to scoring was the
largest for small valuation studies and that the uncertainty around the specification of the model was
found to be a larger contributor to this parameter uncertainty [14].
We have illustrated how acknowledging the possibility of parameter uncertainty leads to wider
confidence intervals and improved coverage probability using both approaches. Across all 249
states, the mean 95% credible intervals widths were 0.0942 (range: 0.0480–0.1149) and 0.0285 (range:
0.002–0.0483) with and without parameter uncertainty, respectively, using PSA. Whilst using the
Bayesian approach, the mean 95% credible intervals widths was 0.1478 (range: 0.053–0.1665). Further,
only 15% of the observed means fell within the 95% CI when ignoring parameter uncertainty, in
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comparison to 36% and 54% when parameter uncertainty is considered, using the PSA and Bayesian
approaches, respectively. Finally, upon quantifying the impact of parameter uncertainty in the
valuations when the SF-6D is used to estimate a population’s mean utility, the true standard error was
underestimated by 79.1% and 86.15% when parameter uncertainty was not accounted for using the
PSA and Bayesian approaches, respectively.
We have shown that the Bayesian approach is superior to the frequentist PSA equivalent for our
presented results as it led to wider credible intervals and improved coverage probability. Another
potential advantage of the Bayesian model is its ability to produce probability distributions describing
the uncertainty in the expected health state values—an increasingly important input to cost effectiveness
analyses for health technology assessment. Although it is common that parameter standard error
estimates give some clue about the uncertainty of estimates, the posterior distributions capture the
full range of uncertainty inherent in these utility estimates. For example, they provide estimates of
the uncertainty in the health state predictions from the model, which the frequentists cannot do. This
leads to the conclusion that the Bayesian method is more flexible in characterizing inputs to regression
models and more comprehensive in characterizing the uncertainty in the model outputs.
Given the centrality of either EQ-5D or SF-6D and the QALY in the international health policy
context, an accurate estimation of health state utility values, along with an understanding of the
uncertainty inherent in these values, becomes paramount for ensuring efficiency in the allocation of
healthcare resources. We have illustrated how parameter uncertainty in the value set can be accounted
for in both PSA and in Bayesian analysis. Currently, parameter uncertainty around the value sets tends
to be ignored in economics evaluations. As a result, this gives committees on reimbursement a false
level of confidence in the evidence and risks reimbursing interventions that are not cost-effective [14].
Following the development of revised tariffs in this research, it will be necessary to ensure
that these can be applied in decision analysis modelling—that is, to explore the implications for
decision uncertainty of using the newly devised method through a comparison of cost-effectiveness
analyses conducted using a standard index value set compared with the revised set developed here.
There is a scope for incorporating the novel methods within economic evaluations using patient-level
data [20–23]. Such evaluations use individual patient health state values in estimating cost-effectiveness.
It is anticipated that in these circumstances the substitution of a fixed utility estimate with the uncertain
estimate will be methodologically straightforward. Further research is required to clarify this.
5. Conclusions
In conclusion, this article evaluates the importance of accounting for parameter uncertainty
around the SF-6D value sets and its impact on studies that use the SF-6D to measure health utility. We
have shown, using two different approaches: PSA and a Bayesian approach, that parameter uncertainty
around the value sets is substantial and should not be ignored in economic evaluations, and thus
should be fully represented when reporting results. Ignoring this additional information could impact
misleadingly on policy decisions.
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